Arch Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a United States-based biotechnology and medical-device company that should be viewed as a specialized small-cap healthcare story rather than a broad pharmaceutical platform. The company was incorporated in 2009 in Nevada, originally under the name Almah, Inc., and later rebranded as Arch Therapeutics, Inc. Public filings describe Arch as a development-stage biotechnology company, and company materials place its headquarters in Framingham, Massachusetts, which situates it within a major U.S. life-sciences cluster. The stock is associated with the U.S. public markets and is referenced in the context of OTC/US equities tied to the NASDAQ/NYSE ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537561/000110465919065500/tm1919813d1_10k.htm?utm_source=openai)) Arch’s core strategy is built around its proprietary AC5® self-assembling technology platform. The company says the platform is designed to rapidly create a physical barrier when applied to tissue, helping achieve hemostasis, control fluid leakage, and manage wounds during surgery, trauma, and interventional care. Its flagship development and commercial efforts center on AC5-branded products, including AC5 Topical Hemostat, AC5 Surgical Hemostat, and the AC5 Advanced Wound System. In practical terms, Arch is targeting surgeon and wound-care workflows where fast bleeding control and tissue protection matter, and it positions its products as a differentiated alternative to traditional hemostatic agents and wound-care materials. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537561/000110465919065500/tm1919813d1_10k.htm?utm_source=openai)) From a competitive standpoint, Arch operates in a crowded and highly regulated field dominated by much larger medtech and wound-care companies. That means its commercial opportunity depends not only on product performance, but also on clinical acceptance, reimbursement dynamics, distribution relationships, and the ability to scale sales efficiently. The company’s small size and development-to-commercialization profile make it more speculative than established healthcare peers, but they also provide optionality if its AC5 platform gains traction in targeted procedural and wound-care segments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537561/000110465919065500/tm1919813d1_10k.htm?utm_source=openai)) Geographically, Arch remains primarily U.S.-focused, although it has disclosed a CE mark for AC5 Topical Hemostat in Europe, indicating that the platform has had at least some regulatory reach outside the United States. Recent company communications have emphasized presentations at wound-care conferences and continued commercialization efforts, including adding contract sales representatives to support the AC5 Advanced Wound System. For investors in France, Belgium, and Switzerland, Arch should be analyzed as a micro-cap medtech company with a potentially interesting barrier-and-hemostasis technology, but with meaningful execution, financing, and adoption risk. The central question is whether the company can convert its technology narrative into sustainable revenue growth. ([ir.archtherapeutics.com](https://ir.archtherapeutics.com/press-releases?utm_source=openai))